Published in Aliment Pharmacol Ther on February 15, 2005
Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol (2008) 1.52
Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity. Therap Adv Gastroenterol (2013) 0.87
Conventional therapy for Crohn's disease. World J Gastroenterol (2006) 0.82
Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Dig Dis Sci (2015) 0.76
Crohn's disease. BMJ Clin Evid (2011) 0.75
Managing refractory Crohn's disease: challenges and solutions. Clin Exp Gastroenterol (2015) 0.75
Crohn's disease. BMJ Clin Evid (2007) 0.75
Collagenous enterocolitis and maturity onset type 1 diabetes manifesting as uraemia, malabsorption and extreme weight loss. BMJ Case Rep (2014) 0.75
Budesonide Use and Hospitalization Rate in Crohn's Disease: Results From a Cohort at a Tertiary Care IBD Referral Center. J Clin Med Res (2016) 0.75
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med (1994) 4.76
Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology (1998) 4.52
Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med (1991) 4.09
Isolation and characterization of adenovirus messenger ribonucleic acid in productive infection. J Virol (1972) 3.83
Selective assay of monomeric and filamentous actin in cell extracts, using inhibition of deoxyribonuclease I. Cell (1978) 3.74
The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther (2002) 3.71
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut (2000) 3.69
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology (2001) 3.60
Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut (2000) 2.86
RNA synthesis and processing in adenovirus-infected cells. Cold Spring Harb Symp Quant Biol (1975) 2.82
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80
A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med (1998) 2.54
Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med (1994) 2.52
Isolation of mRNA from KB-cells by affinity chromatography on polyuridylic acid covalently linked to Sepharose. Eur J Biochem (1972) 2.48
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther (2015) 2.25
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut (2005) 2.22
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther (2010) 2.20
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther (2014) 2.18
Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology (1999) 2.14
Mycophenolate mofetil for Crohn's disease? Lancet (1999) 2.03
Reorganization of actin in platelets stimulated by thrombin as measured by the DNase I inhibition assay. Proc Natl Acad Sci U S A (1979) 2.02
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression. Aliment Pharmacol Ther (2014) 1.96
Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther (2005) 1.96
Analysis of clinical specimens by hybridisation with probe containing repetitive DNA from Plasmodium falciparum. A novel approach to malaria diagnosis. Lancet (1984) 1.92
Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum (1999) 1.79
BIACORE analysis of histidine-tagged proteins using a chelating NTA sensor chip. Anal Biochem (1997) 1.79
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut (2008) 1.75
Identification of the in vitro translation products of adenovirus mRNA by immunoprecipitation. J Virol (1975) 1.74
Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol (2000) 1.71
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther (2013) 1.69
Effect of L-dopa on speech in Parkinsonism. An EMG study of labial articulatory function. J Neurol Neurosurg Psychiatry (1971) 1.63
Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2013) 1.63
Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology (1999) 1.61
Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology (1996) 1.58
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther (2014) 1.56
Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology (1999) 1.56
Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol (2000) 1.56
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther (2009) 1.54
Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology (1995) 1.54
MHC Class II alleles in ulcerative colitis-associated colorectal cancer. Gut (2009) 1.53
Molecular structure of pulmonary surfactant protein D (SP-D). J Biol Chem (1994) 1.51
Occupational exposure to electromagnetic fields in relation to leukemia and brain tumors: a case-control study in Sweden. Cancer Causes Control (1993) 1.51
Incidence of leukaemia and brain tumours in some "electrical occupations". Br J Ind Med (1991) 1.51
Ultra-high-resolution dual-source CT for forensic dental visualization-discrimination of ceramic and composite fillings. Int J Legal Med (2008) 1.47
Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc (1996) 1.47
A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol (1987) 1.47
A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology (2001) 1.47
Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol (2000) 1.46
Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis (2001) 1.46
Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology (1996) 1.46
Characterization of platelet extracts before and after stimulation with respect to the possible role of profilactin as microfilament precursor. Cell (1981) 1.45
Alpha-1-antitrypsin is present in the specific granules of human eosinophilic granulocytes. Clin Exp Allergy (2001) 1.44
Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr (1998) 1.44
Gibberellin-Induced Systemic Fruit Set in a Male-Sterile Tomato. Science (1958) 1.44
Early measles virus infection is associated with the development of inflammatory bowel disease. Am J Gastroenterol (2000) 1.42
Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol (1998) 1.39
Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem (1999) 1.38
Effects of combined pancreatic and renal transplantation on diabetic neuropathy: a two-year follow-up study. Lancet (1987) 1.38
Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis (1999) 1.36
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology (1996) 1.33
Recombinant pulmonary surfactant protein D. Post-translational modification and molecular assembly. J Biol Chem (1994) 1.32
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther (2013) 1.32
Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology (1996) 1.31
PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene (2001) 1.31
Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med (2001) 1.30
Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut (1997) 1.30
The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect Immun (2000) 1.30
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol (2007) 1.28
Cigarette smoking and celiac sprue: a case-control study. Am J Gastroenterol (2001) 1.27
Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther (2007) 1.25
Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut (1996) 1.25
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol (2001) 1.24
Crohn's disease of the esophagus: clinical features and outcomes. Inflamm Bowel Dis (2001) 1.24
Pollen-based quantitative reconstructions of Holocene regional vegetation cover (plant-functional types and land-cover types) in Europe suitable for climate modelling. Glob Chang Biol (2014) 1.21
Highly reiterated non-coding sequence in the genome of Plasmodium falciparum is composed of 21 base-pair tandem repeats. J Mol Biol (1985) 1.21
The LuxR receptor: the sites of interaction with quorum-sensing signals and inhibitors. Microbiology (2005) 1.20
Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology (1998) 1.18
Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1987) 1.18
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther (2010) 1.18
Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology (1999) 1.17
In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet (1988) 1.15
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis (2012) 1.15
Messenger RNA isolation with poly(U) agarose. Methods Enzymol (1974) 1.14
Persistent p53 mutations in single cells from normal human skin. Am J Pathol (2001) 1.14
Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut (2005) 1.13
Understanding Concerns About Treatment-as-Prevention Among People with HIV who are not Using Antiretroviral Therapy. AIDS Behav (2015) 1.13
Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut (2001) 1.12
Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects. Acta Radiol (2007) 1.12
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut (2001) 1.11
The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol (1990) 1.11
Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis (2001) 1.10
MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther (2008) 1.10